Photo of Anupriya Agarwal, Ph.D.

Anupriya Agarwal Ph.D.

  • (503) 494-7599
    • Associate Professor of Medicine School of Medicine
    • Cell and Developmental Biology Graduate Program School of Medicine
    • Molecular and Medical Genetics Graduate Program School of Medicine
    • Cancer Biology Graduate Program School of Medicine
    • Program in Molecular and Cellular Biosciences School of Medicine

The overarching goal of the Agarwal lab is to identify novel drivers of disease initiation, progression, and drug resistance in leukemia and to ultimately translate these discoveries into treatments for leukemia patients. Specifically, our lab is interested in understanding the composite interplay of genetic events and the tumor microenvironment that are requisite for initiating the growth of preleukemic cells, disease evolution from preleukemic to leukemic stage, and conferring drug resistance. To identify novel pathways of disease initiation and drug resistance, we have developed various functional assays, which we employ in tandem with, single cell transcriptomic, genomic, and proteomic approaches. We take a multidisciplinary approach and utilize various state-of-art techniques to dissect the functional role and therapeutic relevance of identified pathways. Our goal is to use this knowledge to improve the understanding of disease pathobiology and inform the development of novel, molecularly targeted therapies for patients.


  • B.S., C. C. S. University, Meerut India 1996
  • M.S., G.B. Pant University, Pantnagar India 1998
  • Ph.D., Dr. R.M.L. Avadh University, Faizabad India 2003

Memberships and associations

  • American Society of Hematology


  • "Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML" Blood September 27 2012
  • "ERK2, but not ERK1, mediates acquired and "De novo" resistance to imatinib mesylate" PLoS One July 1 2009
  • "Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia" Oncogene June 4 2015
  • "A specific need for CRKL in p210BCR-ABL - Induced transformation of mouse hematopoietic progenitors" Journal of Cancer Research September 15 2010
  • "Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia" Clinical Cancer Research April 15 2014
  • "An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia" Leukemia  2008
  • "Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations" Blood March 6 2014
  • "Acute promyelocytic leukemia with JAK2 V617F and severe differentiation syndrome" Leukemia Research Reports January 1 2015
  • "Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML" New England Journal of Medicine  2013
  • "Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins" Proceedings of the National Academy of Sciences of the United States of America November 26 2013
  • "BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein" Blood November 20 2014
  • "Muscle atrophy in response to cytotoxic chemotherapy is dependent on intact glucocorticoid signaling in skeletal muscle" PLoS One September 25 2014
  • "MDS" Blood September 6 2012
  • "Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease" Blood September 1 2008
  • "Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity" Journal of Clinical Investigation January 4 2011
  • "BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia" Journal of Experimental Medicine October 24 2011
  • "The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia" Blood November 10 2011
  • "Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors" Leukemia May 2012
  • "The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in Mice that is responsive to therapeutic JAK inhibition" Blood November 21 2013
  • "Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis" Journal of Cancer Research June 1 2013
  • "TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms" Blood December 8 2011
  • "Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity (Journal of Clinical Investigation (2011) 121, 1, (396-409) DOI" Journal of Clinical Investigation March 1 2011
  • "Cell cycle-dependent regulation of the bi-directional overlapping promoter of human BRCA2/ZAR2 genes in breast cancer cells" Molecular Cancer March 4 2010
  • "JAK2V617I results in cytokine hypersensitivity without causing an overt myeloproliferative disorder in a mouse transduction-transplantation model" Experimental Hematology January 1 2016
  • "CXCR4 antagonists for the treatment of CML"  January 1 2012
  • "Alterations in acute myeloid leukaemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance" British Journal of Haematology March 1 2016
  • "Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism" American Journal of Hematology February 1 2016
  • "Cytokine overproduction and crosslinker hypersensitivity are unlinked in Fanconi anemia macrophages" Journal of Leukocyte Biology March 1 2016
  • "Molecular biology of chronic leukemias"  April 15 2015
  • "Ultrasensitive proteomic quantitation of cellular signaling by digitized nanoparticle-protein counting" Scientific Reports June 20 2016

Additional information

Edit profile